VTGN News and Press, VistaGen Therapeutics Inc. From 06/28/23

2023-06-28 16:32:00 ET VistaGen Therapeutics press release ( NASDAQ: VTGN ): FY GAAP EPS of -$8.51 misses by $0.11 . At March 31, 2023, the Company had cash and cash equivalents of approximately $16.6 million. As of June 27, 2023, the Company had 7,872,479 shares o...

Positive results in Phase 3 open label study of fasedienol (PH94B) in social anxiety disorder (SAD) Positive U.S. Food and Drug Administration (FDA) feedback on the use of the Liebowitz Social Anxiety Scale (LSAS) as the primary efficacy endpoint in future Phase 3 studies of fasedienol in...

Vistagen Therapeutics (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, will host a conference call and webcast today at 1:3...

Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced it will host a conference call and webcast on Wednesday, June 28...

2023-06-23 09:42:51 ET Vistagen ( NASDAQ: VTGN ) received a letter from Nasdaq indicating that the company has regained full compliance with listing rules, the company said Friday. The company said it satisfied Nasdaq's minimum $1.00 bid price per share or greater require...

Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that, on June 22, 2023, Vistagen received a letter from the List...

Vistagen (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has announced favorable safety and tolerability data from its U.S...

The U.S. Phase 1 data build on successful Phase 1 and Phase 2A clinical studies of itruvone previously conducted outside the U.S. Itruvone was well-tolerated and demonstrated a favorable safety and tolerability profile across single and multiple dose intranasal administrations ...

--News Direct-- Vistagen Therapeutics CEO Shawn Singh joined Steve Darling from Proactive to share news about the company that is a late-stage biopharmaceutical company based in South San Francisco, focusing on transforming the treatment options for anxiety disorders, depression disorders...

Vistagen Therapeutics (NASDAQ: VTGN) CEO Shawn Singh will participate in this month’s Healthcare Virtual Conference presented by Maxim Group LLC. The three-day online event is scheduled for June 20–22, 2023, and will be hosted on the M-Vest platform. Vistagen is a late clinical-sta...